Iron Triangle Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Iron Triangle Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-265,076	Closed	-$16.4M	–	36
2022 Q3	$16.4M	Buy	265,076 +115,076	+77%	+$8.04M	2.87%	20
2022 Q2	$12M	Sell	150,000 -353,744	-70%	-$33.5M	1.55%	20
2022 Q1	$53M	Buy	503,744 +266,274	+112%	+$25.9M	6.3%	2
2021 Q4	$25.6M	Sell	237,470 -336,997	-59%	-$36.8M	3.57%	17
2021 Q3	$62.9M	Sell	574,467 -44,106	-7%	-$4.58M	9.03%	1
2021 Q2	$57.9M	Buy	618,573 +118,573	+24%	+$10.9M	5.97%	6
2021 Q1	$46M	Sell	500,000 -150,000	-23%	-$12.7M	5.85%	5
2020 Q4	$47.5M	Buy	650,000 +300,000	+86%	+$22.3M	6.16%	4
2020 Q3	$27.2M	Sell	350,000 -86,127	-20%	-$5.93M	6.08%	4
2020 Q2	$24.2M	Sell	436,127 -63,873	-13%	-$2.73M	6.1%	4
2020 Q1	$14.8M	Buy	500,000 +11,702	+2%	+$396K	5.73%	3
2019 Q4	$17.7M	Buy	+488,298	New	+$15M	4.68%	8

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Iron Triangle Partners's HZNP Position: Q4 2022 in Review

Iron Triangle Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 265,076 shares — an estimated $16.4M sold.

Iron Triangle Partners first reported a position in HZNP in Q4 2019 and held it in 12 quarters. The position peaked at $62.9M in Q3 2021. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Iron Triangle Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Iron Triangle Partners sold 265,076 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $16.4M.
Iron Triangle Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2019 and held it in 12 quarters.
Iron Triangle Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $62.9M in Q3 2021.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Iron Triangle Partners's 13F filing for Q4 2022, filed 14 Feb 2023.